R. Edward Hendrick, PhD
October 2017

The risks and benefits of screening mammography are under constant scrutiny. An obvious risk, and a barrier to some women undergoing screening mammography, is the risk of radiation-induced breast cancer (1). Recently, the increased use of imaging modalities such as computed tomography (CT) has raised concerns about potential cancer induction (2ā€“5). Meanwhile, recently introduced breast imaging modalities such as breast-specific gamma imaging (BSGI) and positron emission mammography (PEM) have been approved by the U.S. Food and Drug Administration and introduced into clinical use as diagnostic adjuncts to mammography and breast ultrasonography (US). These modalities may be considered for breast cancer screening, particularly in women at higher risk for breast cancer. Other recently introduced breast imaging modalities such as digital breast tomosynthesis and dedicated breast CT are the focus of clinical investigation for U.S. Food and Drug Administration approval and also may be considered for screening in some women, such as those with dense breasts, since they offer the potential to unmask cancers obscured by dense fibroglandular tissue on mammograms.

Read more: http://pubs.rsna.org/doi/full/10.1148/radiol.10100570